Skip to main content
. 2016 Dec 1;8(2):2659–2671. doi: 10.18632/oncotarget.13736

Figure 2. IL-10 with inhibitory effects on T-cell activation is induced at early time points after vaccination.

Figure 2

(A) C57BL/6 mice (n = 5/time-point) were vaccinated with OVA+Imiquimod and IL-10 mRNA was quantified by qPCR at different time-points in purified DC and CD4 cells. (B) Vert-X mice (n = 8/group) were vaccinated with OVA+Imiquimod, OVA+poly(I:C) or left untreated (UT) and one week later the percentage of splenic IL-10-producing cells was determined by flow cytometry. (C) C57BL/6 mice (n = 4) were vaccinated with OVA+Imiquimod or OVA+poly(I:C) and one week later splenocytes were stimulated with PMA/Ionomycin and intracellular IL-10 was determined by flow cytometry. (D) C57BL/6 mice (n = 4) were vaccinated with OVA+Imiquimod with or without blockade of IL-10 at day four after vaccination. At day 7, OVA-specific responses were determined by ELISPOT. Results are representative of 2 independent experiments.